Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

Case Study: Using ‘Journey to the Future’ projective techniques to understand evolving customer expectations

Our client was developing a portfolio of innovative treatments and was in the process of recruiting a sales force to support the promotion of this portfolio. Research was required to...

Inizio

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

Bristol-Myers Squibb (BMS) building

Opdivo gets green light for Hodgkin lymphoma in Europe

Becomes the first PD-1 inhibitor to receive EU licence in this indication

Creative marketing and compliance

The challenge of addressing this fine balancing act

Shield Therapeutics’ CFO steps down

Richard Jones to leave the group in early 2017

Am I all grown up yet? My first year in a real, adult, full-time job.

One year at Say Communications has whizzed by. I’m in my early twenties and a recent graduate who has spent the last year working in healthcare communications.  Now that my...

Say Communications

- PMLiVE

McCann Health and Langland lead Global Awards 2016 winners

Collect best global network and best agency awards for fifth consecutive year

Lucid strengthens its creative services department

There’s no slowing down for Lucid Group as it completes its first decade of trading early next year. In parallel with the recent appointments in its senior leadership team, Lucid...

Lucid Group Communications Limited

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

AstraZeneca AZ

Trials of AZ’s durvalumab restart as FDA hold is relaxed

Bleeding side effects in two head and neck cancer studies not attributed to the PD-L1 inhibitor

- PMLiVE

An exciting outlook for pre-approval access and compassionate use

How to deal with the ethical and practical considerations of the demand for promising new drugs that are in development

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links